Posterliste

Einen zeitlichen Übersichtsplan aller Veranstaltungen finden Sie im Konferenzplaner.

Filter
Code
Titel
P01
Patient satisfaction with the first talk about diagnosis and its impact on treatment decisions: a Swiss Multiple Sclerosis Registry study
Poster SNG / SSN
L. Barin Präsentierende:r Universität Zürich, Institut für Epidemiologie, Biostatistik und PräventionV. von Wyl Universität Zürich, Institut für Epidemiologie, Biostatistik und PräventionM. Kaufmann Universität Zürich, Institut für Epidemiologie, Biostatistik und PräventionM. Lutz Schweizerische Multiple Sklerose GesellschaftC. Pot CHUV LausanneS. Schippling University Hospital ZurichA. Salmen Inselspital, Universitätsspital Bern und Universität BernP. Calabrese University of Basel, Behavioral Neurology and Neuropsychology, Division of Molecular and Cognitive NeuroscienceS. Müller Kantonsspital St. GallenA. Chan Inselspital, Universitätsspital Bern und Universität BernJ. Kesselring Rehabilitation Centre Kliniken ValensC. Kamm Luzerner Kantonsspital
P02
MANAGEMENT OF PATIENTS WITH MINOR CLINICAL DEFICITS DESPITE A LARGE CEREBRAL VESSEL OCCLUSION
Poster SNG / SSN
B. Volbers Präsentierende:r Inselspital, Universitätsspital BernR. Häussler Universitätsklinikum ErlangenT. Struffert Universitätsklinikum ErlangenA. Marsch Universitätsklinikum ErlangenK. Macha Universitätsklinikum ErlangenS. Schwab Universitätsklinikum ErlangenA. Dörfler Universitätsklinikum ErlangenB. Kallmünzer Universitätsklinikum Erlangen
P03
Systemic review and meta-analysis of haematoma location and morphology of anticoagulation-associated intracerebral haemorrhage
Poster SNG / SSN
D. Seiffge Präsentierende:r Universitätsspital BaselS. Curtze Helsinki University HospitalN. Dequatre-Ponchelle National Institute of Health and Medical Research U1171, Degenerative and Vascular Cognitive Disorders, Lille University HospitalA. Pezzini Neurology Clinic University of BresciaT. Tatlisumak Institute of Neurosciences and Physiology, Sahlgrenska Academy at University of GothenburgC. Cordonnier National Institute of Health and Medical Research U1171, Degenerative and Vascular Cognitive Disorders, Lille University HospitalD. Werring Department of Brain Repair and Rehabilitation, UCL Institute of Neurology and The National Hospital for Neurology and Neurosurgery, Queen Square
P04
Neuroinflammation may have a beneficial effect on experimental stroke
Poster SNG / SSN
K. Guse Präsentierende:r Inselspital, Bern University Hospital, Department for BioMedical Research (DBMR), University of Bern, SwitzerlandN. Hagemann University of Duisburg-Essen, GermanyL. Schrewe Inselspital, Bern University Hospital, Department for BioMedical Research (DBMR), University of Bern, SwitzerlandA. Salmen Inselspital, Bern University Hospital, Department for BioMedical Research (DBMR), University of Bern, SwitzerlandR. Hoepner Inselspital, Bern University Hospital, Department for BioMedical Research (DBMR), University of Bern, SwitzerlandD. Hermann University of Duisburg-Essen, GermanyA. Chan Inselspital, Bern University Hospital, Department for BioMedical Research (DBMR), University of Bern, Switzerland
P05
Inhibition of c-Jun N-terminal kinase as new therapeutic approach for treatment of multiple sclerosis
Poster SNG / SSN
M. Briner Präsentierende:r Inselspital, Universitätsspital BernM. Bagnoud Inselspital, Universitätsspital BernK. Guse Inselspital, Universitätsspital BernA. Salmen Inselspital, Universitätsspital BernA. Chan Inselspital, Universitätsspital BernR. Hoepner Inselspital, Universitätsspital BernL. Schrewe Inselspital, Universitätsspital Bern
P06
State space velocity: a novel quantitative predictive marker in hypoxic-ischemic encephalopathy
Poster SNG / SSN
E. Efthymiou Präsentierende:r Universitätsspital ZürichR. Renzel Universitätsspital ZürichR. Poryazova Universitätsspital ZürichL. Imbach Universitätsspital Zürich
P07
STRAW-II „STRoke AWareness“ - Awareness of Stroke in a small region of Switzerland
Poster SNG / SSN
J. Walch Präsentierende:r C. Berger Neurologie Praxis SargansU. Keller Pizol Care PraxisT. Hatziisaak Pizol Care Praxis
P08
Preliminary Experience with a Novel Drug Coating Balloon Catheter for Symptomatic Intracranial High-grade Stenosis
Poster SNG / SSN
P. Gruber Präsentierende:r Kantonsspital Aarau AGT. Kahles Kantonsspital Aarau AGJ. Berberat Kantonsspital Aarau AGM. Hlavica Kantonsspital Aarau AGJ. Anon Kantonsspital Aarau AGM. Diepers Kantonsspital Aarau AGK. Nedeltchev Kantonsspital Aarau AGL. Remonda Kantonsspital Aarau AG
P09
Comparison of New-Generation Double-Layer Micromesh Carotid Stent-System versus Carotid Self-expanding Hybrid Stent System in Symptomatic Carotid Artery Stenosis
Poster SNG / SSN
P. Gruber Präsentierende:r Kantonsspital Aarau AGT. Kahles Kantonsspital Aarau AGJ. Berberat Kantonsspital Aarau AGJ. Anon Kantonsspital Aarau AGM. Diepers Kantonsspital Aarau AGK. Nedeltchev Kantonsspital Aarau AGL. Remonda Kantonsspital Aarau AG
P10
Reasons for Prehospital Delay in Acute Ischemic Stroke: a Prospective Cohort Study
Poster SNG / SSN
J. Fladt Präsentierende:r Universitätsspital BaselN. Meier Universitätsspital BaselD. Seiffge Universitätsspital BaselC. Tränka Universitätsspital BaselA. Polymeris Universitätsspital BaselS. Thilemann Universitätsspital BaselR. Sutter Universitätsspital BaselH. Gensicke Universitätsspital BaselN. Peters Universitätsspital BaselL. Bonati Universitätsspital BaselS. Engelter Universitätsspital BaselP. Lyrer Universitätsspital BaselG. De Marchis Universitätsspital Basel
P11
Papilledema or Papillitis? - Case report: A rare presentation of Neurosyphilis
Poster SNG / SSN
P. Balcerak Präsentierende:r Kantonsspital St. GallenD. Flügel Kantonsspital St. GallenJ. Heckmann Kantonsspital St. GallenV. Sturm Kantonsspital St. GallenB. Tettenborn Kantonsspital St. Gallen
P12
The impact of collaterals on reperfusion in stroke
Poster SNG / SSN
N. Binder Präsentierende:r Universitätsspital ZürichM. El Amki Universitätsspital ZürichM. Wyss Universität ZürichT. Najimi Universitätsspital ZürichB. Weber Universität ZürichS. Wegener Universitätsspital Zürich
P13
Crossed Cerebellar Diaschisis after stroke: a vascular phenomen?
Poster SNG / SSN
L. von Bieberstein Präsentierende:r B. Van Niftik Universitätsspital Zürich, Clinical Neuroscience Center, Zurich, SwitzerlandM. Sebök Universitätsspital Zürich, Clinical Neuroscience Center, Zurich, SwitzerlandM. Piccirelli Universitätsspital Zürich, Clinical Neuroscience Center, Zurich, SwitzerlandO. Bozinov Universitätsspital Zürich, Clinical Neuroscience Center, Zurich, SwitzerlandL. Regli Universitätsspital Zürich, Clinical Neuroscience Center, Zurich, SwitzerlandA. Luft Universitätsspital Zürich, Clinical Neuroscience Center, Zurich, SwitzerlandJ. Fierstra Universitätsspital Zürich, Clinical Neuroscience Center, Zurich, SwitzerlandS. Wegener Universitätsspital Zürich, Clinical Neuroscience Center, Zurich, Switzerland
P14
Eligibility for late thrombectomy using DAWN, DEFUSE-3 and more liberal selection criteria in a comprehensive stroke center
Poster SNG / SSN
S. Nannoni Präsentierende:r Centre Hospitalier Universitaire Vaudois and University of LausanneD. Strambo CHUV-University HospitalG. Sirimarco CHUV-University HospitalA. Eskandari CHUV LausanneV. Dunet CHUV-University HospitalG. Saliou CHUV-University HospitalM. Wintermark Stanford UniversityM. Patrik CHUV Lausanne
P15
Sensorimotor stroke alters hippocampo-thalamic network activity: A Manganese-enhanced Magnetic Resonance Imaging study
Poster SNG / SSN
P. Baumgartner Präsentierende:r Universitätsspital ZürichM. El Amki Universitätsspital ZürichO. Bracko Universitätsspital ZürichA. Luft Universitätsspital ZürichS. Wegener Universitätsspital Zürich
P16
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Erenumab on Exercise Time During a Treadmill Test in Patients with Stable Angina
Poster SNG / SSN
C. Depre Amgen Inc.L. Antalik Regional HospitalA. Starling Mayo ClinicM. Arzt Jacksonville Center for Clinical ResearchO. Eisele Amgen Inc.Y. Kubo Amgen Inc.R. Lenz Amgen Inc.D. Mikol Amgen Inc.M. Arzt Präsentierende:r Novartis Pharma Schweiz AG
P17
Use of Acute Headache and Migraine Medications in Patients with Episodic Migraine in the STRIVE Phase 3 Trial of Erenumab for Migraine Prevention
Poster SNG / SSN
U. Reiter Charité - Universitätsmedizin BerlinJ. Bonner Mercy ResearchG. Broessner Medical University of InnsbruckY. Hallstrom Stockholm Neuro CenterH. Picard Amgen Inc.S. Cheng Amgen Inc.F. Zhang Amgen Inc.D. Mikol Amgen Inc.J. Klatt Novartis Pharma AGM. Arzt Präsentierende:r Novartis Pharma Schweiz AG
P18
Erenumab Safety Among Migraine Patients Using Triptans or With Cardiovascular (CV) Risk Factors
Poster SNG / SSN
P. Winner Nova Southeastern UniversityU. Reiter Charité - Universitätsmedizin BerlinD. Kudrow Mayo ClinicD. Kudrow California Medical Clinic for HeadacheJ. Rozniecki Medical University of LodzF. Xue Amgen Inc.F. Zhang Amgen Inc.S. Cheng Amgen Inc.H. Picard Amgen Inc.D. Mikol Amgen Inc.M. Arzt Präsentierende:r Novartis Pharma Schweiz AG
P19
Tolerability and Quality of Life in Patients with Multiple Sclerosis Switched to Intramuscular Interferon Beta 1a Autoinjector (Avonex® Pen™): SFERA Study
Poster SNG / SSN
C. Gobbi Präsentierende:r Regional Hospital Lugano (EOC)C. Zecca Präsentierende:r Regional Hospital Lugano (EOC)L. Panicari Regional Hospital Lugano (EOC)P. Zbysek Lékařská fakulta v Hradci KrálovéK. Prikrylova Biogen (Czech Republic) s.r.o.,M. Ghielmetti Biogen Switzerland AGA. Beeler Biogen Switzerland AG
P20
Acetazolamide-responsive episodic ataxia linked to novel splice site variant in FGF14 gene
Poster SNG / SSN
M. Schesny University Hospital ZurichF. Joncourt University Hospital BerneA. Tarnutzer Präsentierende:r Universitätsspital Zürich
P21
Safety of Ocrelizumab in Multiple Sclerosis: Updated Analysis in Patients with Relapsing and Primary Progressive Multiple Sclerosis
Poster SNG / SSN
T. Derfuss Präsentierende:r University Hospital BaselN. Goebels University Hospital DüsseldorfS. Hauser University of California San FranciscoX. Montalban University of Toronto, Vall d’Hebron University HospitalH. Koendgen F. Hoffmann-La Roche LtdC. Li F. Hoffmann-La Roche LtdC. Marcillat F. Hoffmann-La Roche LtdA. Pradhan Genentech, Inc.D. Wormser F. Hoffmann-La Roche LtdJ. Wolinsky McGovern Medical School, UTHealthL. Kappos University Hospital Basel
P22
Annualized Relapse Rate and Confirmed Disability Progression in Patients Receiving Continuous Ocrelizumab or Switching From Interferon beta-1a to Ocrelizumab in the Open-Label Extension Period of the Phase III Trials of Ocrelizumab in Patients With RMS
Poster SNG / SSN
C. Gobbi Präsentierende:r Neurocenter of Southern Switzerland, Ospedale CivicoB. Brochet University of BordeauxX. Montalban University of Toronto, Vall d’Hebron University HospitalR. Naismith Washington University School of MedicineJ. Wolinsky McGovern Medical School, UTHealthM. Manfrini F. Hoffmann-La Roche LtdM. Garas F. Hoffmann-La Roche LtdP. Villoslada-Diaz Genentech, Inc.F. Model F. Hoffmann-La Roche LtdS. Hubeaux F. Hoffmann-La Roche LtdS. Hauser University of California, San FranciscoL. Kappos University Hospital Basel
P23
Une brève histoire des blocs de conduction nerveux
Poster SNG / SSN
F. Ochsner Präsentierende:r Cabinet médical Dr med François Ochsner
P24
Suppression of MRI Dsease Activity and Slowing of Brain Volume Loss Over 7 Years in Alemtuzumab-Treated Patients with Active RRMS: CARE-MS I (TOPAZ Study)
Poster SNG / SSN
S. Schippling Präsentierende:r University Hospital Zürich and University of ZürichD. Arnold NeuroRx Research and McGill UniversityM. Barnett University of SydneyG. Comi University Vita-Salute San RaffaeleA. Rovira Vall d'Hebron University HospitalA. Traboulsee University of British ColumbiaL. Chung SanofiN. Daizadeh SanofiK. Nakamura Cleveland ClinicB. Van Wijmeersch Hasselt UniversityD. Pelletier Keck School of Medicine of University of Southern California
P25
Benefits of Successful Reperfusion in Patients Presenting with ASPECTS 0-5
Poster SNG / SSN
J. Käsmacher Präsentierende:r Inselspital, Universitätsspital BernP. Chaloulos-Iakovidis Inselspital, Universitätsspital BernL. Panos Inselspital, Universitätsspital BernP. Mordasini Inselspital, Universitätsspital BernP. Michel CHUV LausanneS. Hajdu CHUV LausanneM. Ribo Hospital Vall d'HebronM. Requena Hospital Vall d'HebronC. Maegerlein Klinikum rechts der Isar der Technischen Universität MünchenB. Friedrich Klinikum rechts der Isar der Technischen Universität MünchenV. Costalat CHU MontpellierA. Benali CHU MontpellierL. Pierrot CHU ReimsM. Gawlitza CHU ReimsV. Pereira University of TorontoJ. Gralla Inselspital, Universitätsspital BernU. Fischer Inselspital, Universitätsspital Bern
P26
Fast and fully-automated, deep learning-based brainstem segmentation method provides accurate and reliable brainstem segmentation in Multiple Sclerosis
Poster SNG / SSN
L. Sander Präsentierende:r Universitätsspital BaselS. Andermatt Universität BaselS. Pezold Universität BaselM. Amann Universität BaselD. Meier Universität BaselT. Sinnecker Universitätsspital BaselM. Wendebourg Universitätsspital BaselY. Naegelin Universitätsspital BaselC. Granziera Universitätsspital BaselL. Kappos Universitätsspital BaselJ. Wuerfel Universität BaselP. Cattin Universität BaselR. Schlaeger Universitätsspital Basel
P27
Brainstem atrophy in Multiple Sclerosis quantified by new segmentation method correlates with disability.
Poster SNG / SSN
L. Sander Präsentierende:r Universitätsspital BaselS. Pezold Universität BaselS. Andermatt Universität BaselM. Amann Universität BaselM. Wendebourg Universitätsspital BaselT. Sinnecker Universitätsspital BaselY. Naegelin Universitätsspital BaselC. Granziera Universitätsspital BaselL. Kappos Universitätsspital BaselJ. Wuerfel Universität BaselP. Cattin Universität BaselR. Schlaeger Universitätsspital Basel
P28
Efficacy of Cladribine Tablets in patients with highly active relapsing-remitting multiple sclerosis: analysis of pooled double-blind data from the CLARITY and ONWARD studies
Poster SNG / SSN
G. Giovannoni Barts and The London School of Medicine and DentistryX. Montalban St Michael’s Hospital, University of TorontoK. Rammohan University of Miami School of MedicineS. Cook Rutgers, The State University of New JerseyG. Comi Università Vita-Salute San Raffaele, Ospedale San RaffaeleP. Rieckmann Medical Park Loipl and University of ErlangenP. Soelberg-Sorensen University of Copenhagen, RigshospitaletP. Vermersch Université de Lille, CHU LilleF. Dangond EMD Serono Research and Development Institute Inc.J. King Royal Melbourne HospitalS. Roy Präsentierende:r MerckD. Damian EMD Serono Research and Development Institute Inc.
P29
Long-term lymphocyte counts in patients with RRMS treated with cladribine tablets
Poster SNG / SSN
P. Soelberg-Sorensen University of Copenhagen, RigshospitaletF. Dangond EMD Serono Research and Development Institute Inc.C. Hicking Merck KGaAS. Roy Präsentierende:r MerckG. Giovannoni Barts and The London School of Medicine and Dentistry
P30
Cladribine Tablets produce selective and discontinuous reduction of B and T lymphocytes and NK cells in patients with early and relapsing MS
Poster SNG / SSN
O. Stuve University of Texas, Southwestern Medical CenterP. Soelberg-Sorensen University of Copenhagen, RigshospitaletG. Giovannoni Barts and The London School of Medicine and DentistryT. Leist Thomas Jefferson UniversityY. Hyvert EMD Serono Research and Development Institute Inc.D. Damian EMD Serono Research and Development Institute Inc.S. Roy Präsentierende:r MerckU. Boschert EMD Serono Research and Development Institute Inc.
P31
If a family forgets – a familiar transient global amnesia in an Italian family.
Poster SNG / SSN
J. Henze Präsentierende:r Spital LinthD. Czell Spital Linth
P32
Efficacy and safety of erenumab in episodic migraine patients with 2–4 prior preventive treatment failures: Results from the Phase 3b LIBERTY study
Poster SNG / SSN
U. Reiter Charité - Universitätsmedizin BerlinP. Goadsby Kings College LondonM. Arzt Centre Hospitalier Universitaire de NiceM. Arzt Leiden University Medical CenterS. Wen NovartisJ. Klatt NovartisR. Agosti Präsentierende:r KopfwehZentrum Hirslanden Zürich
P33
Treatment satisfaction, quality of life and fatigue in teriflunomide-treated patients in the real-world setting in Switzerland: The Teri-EASY study design
Poster SNG / SSN
C. Gobbi Präsentierende:r Civic Hospital of LuganoC. Kaiser SanofiN. Roesch Sanofi
P34
Next generation sequencing is a promising tool for the diagnosis of hereditary neuropathies
Poster SNG / SSN
T. Kuntzer Präsentierende:r CHUV, service de neurologieJ. Good CHUV, Department of MedicineC. Tran CHUV, Department of MedicineS. Unger CHUV, Department of MedicineH. Fodstad CHUV, Department of MedicineL. Mittaz Crettol CHUV, Department of MedicineB. Royer-Bertrand CHUV, Department of MedicineA. Superti-Furga CHUV, Department of Medicine
P35
Ozanimod (RPC1063) reduces plasma levels of neurofilament light chain in patients with relapsing multiple sclerosis: Results from RADIANCE Part A, a randomized, placebo-controlled, phase 2 study
Poster SNG / SSN
J. Kuhle Präsentierende:r Neurologic Clinic and Policlinic, University Hospital of Basel, University of Basel, Basel, Switzerland
P36
Patient-Reported and Clinical Outcomes in Teriflunomide-Treated Patients with Relapsing Remitting Multiple Sclerosis: Results from the Real-World TACO Study
Poster SNG / SSN
C. Gobbi Präsentierende:r Civic Hospital of LuganoL. Achtnichts Canton Hospital AarauT. Derfuss University Hospital BaselP. Stellmes Neurologie am LöwenplatzC. Kamm Canton HospitalR. Agosti Headache Center Zurich HirslandenA. Czaplinski Klinik Hirslanden ZürichA. Salmen Dept. of Neurology, Inselspital Bern, University Hospital and University of BernC. Zecca Regional Hospital LuganoN. Roesch Sanofi
P37
Brain MRI Activity and Atrophy Measures in Patients Receiving Continuous Ocrelizumab or Switching From Interferon ß-1a to Ocrelizumab in the Open-Label Extension Period of the Phase III Trials of Ocrelizumab in Patients With Relapsing Multiple Sclerosis
Poster SNG / SSN
L. Kappos Präsentierende:r Universitätsspital BaselD. Arnold McGill UniversityS. Hauser University of CaliforniaX. Montalban University of TorontoA. Traboulsee University of British ColumbiaJ. Wolinsky McGovern Medical School, UTHealthV. Levesque Genentech Inc.P. Villoslada Genentech, Inc.S. Belachew F. Hoffmann-La Roche Ltd.F. Model F. Hoffmann-La Roche Ltd.S. Hubeaux F. Hoffmann-La Roche Ltd.A. Bar-Or University of Pennsylvania
P38
Effect of Teriflunomide on Greater Disability Worsening in Patients With Relapsing Forms of MS in a Pooled Analysis of the Phase 3 TEMSO and TOWER Studies
Poster SNG / SSN
L. Kappos Präsentierende:r Universitätsspital BaselA. Miller Icahn School of Medicine at Mount Sinai, New YorkE. Poole SanofiJ. Chavin SanofiP. Truffinet SanofiM. Freedman University of Ottowa and the Ottawa Hospital Research Institute
P39
Functional impact of apoE on abcg2-specific therapeutic substrates of neuroimmunological diseases
Poster SNG / SSN
L. Schrewe Präsentierende:r Inselspital, Bern University Hospital, Department for BioMedical Research (DBMR), University of Bern, SwitzerlandK. Guse Inselspital, Bern University Hospital, Department for BioMedical Research (DBMR), University of Bern, SwitzerlandR. Hoepner Inselspital, Bern University Hospital, Department for BioMedical Research (DBMR), University of Bern, SwitzerlandA. Salmen Inselspital, Bern University Hospital, Department for BioMedical Research (DBMR), University of Bern, SwitzerlandN. Hagemann University of Duisburg-Essen, GermanyD. Hermann University of Duisburg-Essen, GermanyF. Lühder Institute for Multiple Sclerosis, University Medical Center Göttingen, Göttingen, GermanyA. Chan Inselspital, Bern University Hospital, Department for BioMedical Research (DBMR), University of Bern, Switzerland
P40
Pharmacological Manipulation of the Endocannabinoid System in a Preclinical Model of Post-Traumatic Stress Disorder
Poster SNG / SSN
A. Vimalanathan Präsentierende:r University of TorontoM. Diwan Centre for Addiction and Mental HealthJ. Nobrega Centre for Addiction and Mental HealthC. Hamani Sunnybrook Health Sciences Centre/ University of Toronto
P41
Unilateral MR guided High Intensity Focused Ultrasound in Parkinson’s disease or essential tremor seems to be save concerning Dysphagia and Dysarthria
Poster SNG / SSN
S. Hägele-Link Präsentierende:r Kantonsspital St. GallenN. Wegener Kantonsspital St. GallenS. Schreglmann Sobell Department of Motor Neuroscience and Movement Disorders, University CollegeJ. Rosenfeld Kantonsspital St. GallenM. Mueller-Baumberger Kantonsspital St. GallenR. Bauer Kantonsspital St. GallenB. Werner University Children´s Hospital, Zurich, SwitzerlandE. Martin Universitäts- Kinderspital ZürichG. Kägi Kantonsspital St. Gallen
P42
P43
P44
High relapse activity in a fingolimod-treated multiple sclerosis patient
Poster SNG / SSN
A. Lascano Präsentierende:r Hôpitaux Universitaires de GenèveG. Bréville Hôpitaux Universitaires de GenèveP. Lalive Hôpitaux Universitaires de GenèveD. Merkler Hôpitaux Universitaires de Genève
P45
IL-8 as a potential biomarker in Guillain-Barre Syndrome
Poster SNG / SSN
A. Lascano Präsentierende:r Hôpitaux Universitaires de GenèveG. Bréville Hôpitaux Universitaires de GenèveP. Lalive Hôpitaux Universitaires de Genève